Overactive Bladder

  • Visha K. Tailor
  • G. Alessandro DigesuEmail author


Overactive bladder (OAB) is a prevalent symptom syndrome that becomes more prevalent with increasing age with an unclear aetiology. OAB is often associated with the urodynamic finding of detrusor overactivity. Symptoms include urinary urgency, frequency and nocturia and may or not be associated with urinary incontinence. The condition is known to have a significant impact on quality of life. Assessment of OAB requires a thorough assessment of patients’ medical history, examination and severity assessment before commencing treatment.

Treatment of OAB is often multimodal with lifestyle changes and pharmacotherapy. Refractory OAB can be described as failure to respond to medical management of OAB. Alternative second-line treatments with intra-vesical injections of botulinum A toxin and neuromodulation methods can be highly effective however are invasive and expensive and can require long-term follow-up with top-up treatments. In absolute refractory cases, surgery can be considered. These are discussed further.


Overactive bladder Detrusor overactivity Urinary frequency Botulinum A toxin Tricyclic antidepressants Desmopressin β3-adrenoceptor agonist Anti-muscarinic drugs Oestrogen 


  1. 1.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.CrossRefGoogle Scholar
  2. 2.
    Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.CrossRefGoogle Scholar
  3. 3.
    Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women. Results from the NOBLE programme. Int Urogynaecol J. 2001;12:S66.Google Scholar
  4. 4.
    Hakimi S, Aminian E, Charandabi SMA, et al. Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. Urologia J. 2018;85:10–4.CrossRefGoogle Scholar
  5. 5.
    Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel: Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Maturitas. 2014;79:349–54.CrossRefGoogle Scholar
  6. 6.
    Stamm WE, Raz R. Factors contributing to susceptibility of postmenopausal women to recurrent urinary tract infections. Clin Infect Dis. 1999;28:723–72.CrossRefGoogle Scholar
  7. 7.
    Balachandran AA, Wildman SS, Strutt M, Duckett J. Is chronic urinary infection a cause of overactive bladder? Eur J Obstet Gynecol Reprod Biol. 2016;201:108–12.CrossRefGoogle Scholar
  8. 8.
    Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142–73.CrossRefGoogle Scholar
  9. 9.
    Hessdoerfer E, Jundt K, Peschers U. Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder? Int Urogynecol J. 2011;22:229–32.CrossRefGoogle Scholar
  10. 10.
    Cutner A. Uroflowmetry. In: Cardozo L, editor. Urogynaecology. London: Churchill Livingstone; 1997. p. 109–16.Google Scholar
  11. 11.
    Henry Lai H, Rawal A, Shen B, Vetter J. The relationship between anxiety and overactive bladder/urinary incontinence symptoms in the clinical population. Urology. 2016;98:50–7.CrossRefGoogle Scholar
  12. 12.
    Llaneza P, García-Portilla MP, Llaneza-Suárez D, Armott B, Pérez-López FR. Depressive disorders and the menopause transition. Maturitas. 2012;71(2):120–30.CrossRefGoogle Scholar
  13. 13.
    Shy M, Fletcher SG. Objective evaluation of overactive bladder: which surveys should I use? Curr Bladder Dysfunct Rep. 2013;8(1):45–50. Scholar
  14. 14.
    Vij M, Srikrishna S, Robinson D, Cardozo L. Quality assurance in quality of life assessment—measuring the validity of the King’s Health Questionnaire. Int Urogynecol J. 2014;25(8):1133–5.CrossRefGoogle Scholar
  15. 15.
    Hashim M, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175:191–5.CrossRefGoogle Scholar
  16. 16.
    Liedl B, Goeschen K, Sutherland SE, Roovers JP, Yassouridis A. Can surgical reconstruction of vaginal and ligamentous laxity cure overactive bladder symptoms in women with pelvic organ prolapse? BJU Int. 2019;123(3):493–510.CrossRefGoogle Scholar
  17. 17.
    Robinson D, Giarenis I, Cardozo L. You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms. Maturitas. 2014;79(1):8–13.CrossRefGoogle Scholar
  18. 18.
    Majumdar A, Hassan I, Saleh S, et al. Inpatient bladder retraining: is it beneficial on its own? Int Urogynecol J Pelvic Floor Dysfunct. 2010;21:657–63.CrossRefGoogle Scholar
  19. 19.
    Geller EJ, Crane AK, Wells EC, et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in post-menopausal women. Clin Drug Investig. 2012;32(10):697–705.CrossRefGoogle Scholar
  20. 20.
    Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J. 2011;5(5 Suppl 2):S139–42. Scholar
  21. 21.
    Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ. 2013;347:f5170.CrossRefGoogle Scholar
  22. 22.
    Nitti VW, Khullar V, Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.CrossRefGoogle Scholar
  23. 23.
    Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2014;6:1–16.Google Scholar
  24. 24.
    Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;(10):CD001405.Google Scholar
  25. 25.
    Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.Google Scholar
  26. 26.
    Simunić V, Banović I, Ciglar S, et al. Local Oestrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82(2):187–97.CrossRefGoogle Scholar
  27. 27.
    Matarazzo MG, Caruso S, Giunta G, Valenti G, Sarpietro G, Cianci A. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause? Eur J Obstet Gynecol Reprod Biol. 2018;222:75–9.CrossRefGoogle Scholar
  28. 28.
    Rufford J, Hextall A, Cardozo L, et al. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J. 2003;14:78.CrossRefGoogle Scholar
  29. 29.
    Robinson D, Cardozo L. Urogynaecology: urinary incontinence. In: Edmunds K, editor. Dewhursts textbook of obstetrics and gynaecology. 8th edn. London: Wiley-Blackwell; 2012. p. 109–116 (Churchill Livingstone. p. 1997).CrossRefGoogle Scholar
  30. 30.
    Wein AJ. Diagnosis and treatment of the overactive bladder. Urology. 2003;62:20–7.CrossRefGoogle Scholar
  31. 31.
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.CrossRefGoogle Scholar
  32. 32.
    Wong J, Tincello DG, Management of refractory overactive bladder. Obstet Gynaecol. 2016;18:173–81.Google Scholar
  33. 33.
    Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28(6):845–50.CrossRefGoogle Scholar
  34. 34.
    de Wall LL, Heesakkers JPFA. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 2017;9:145–57.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189:2194–201.CrossRefGoogle Scholar
  36. 36.
    Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175:835–41.CrossRefGoogle Scholar
  37. 37.
    Veeratterapillay R, Thorpe AC, Harding C. Augmentation cystoplasty: contemporary indications, techniques and complications. Indian J Urol. 2013;29(4):322–7.CrossRefGoogle Scholar
  38. 38.
    Moon A, Vasdev N, Thorpe AC. Continent urinary diversion. Indian J Urol. 2013;29(4):303–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of UrogynaecologyImperial College NHS TrustLondonUK

Personalised recommendations